Clinical Scorecard: Accelerated metastatic development of primary pulmonary synovial sarcoma despite adherence to multimodal treatment guidelines: a case study
At a Glance
Category
Detail
Condition
Primary Pulmonary Synovial Sarcoma (PPSS)
Key Mechanisms
Characterized by chromosomal translocation t(X,18)(p11;q11) resulting in SYT-SSX fusion.
Target Population
Young adults, median age 40-50 years.
Care Setting
Oncology specialty center.
Key Highlights
PPSS accounts for less than 0.5% of all primary lung malignancies.
No known association with tobacco exposure or environmental carcinogens.
Aggressive clinical course with common recurrence and metastasis.
Definitive diagnosis requires biopsy and molecular confirmation of SS18-SSX fusion.
Optimal multimodal therapy may not prevent rapid metastatic progression.
Guideline-Based Recommendations
Diagnosis
Tumor biopsy with histopathology and immunohistochemistry.
Molecular confirmation of SS18-SSX fusion.
Management
Neoadjuvant chemotherapy followed by surgical resection.
Monitoring & Follow-up
Surveillance imaging post-treatment to assess for recurrence or metastasis.
Risks
High risk of aggressive disease progression despite initial treatment response.
Patient & Prescribing Data
Older adults with a history of smoking and comorbidities.
Neoadjuvant chemotherapy with Adriamycin, Ifosfamide, and Mesna was utilized.
Clinical Best Practices
Consider referral to a sarcoma specialty center for management.
Emphasize the need for targeted systemic therapies and access to clinical trials.
